BC Week In Review | Jan 5, 2009
Clinical News

Destiny Max regulatory update

Trinity Biotech submitted a 510(k) application to FDA for its Destiny Max hemostasis analyzer to measure mechanical and optical clot detection. The company expects a decision in 2Q09. The high throughput coagulation analyzer is marketed...
BC Week In Review | Jan 5, 2009
Company News

Trinity sales and marketing update

Trinity launched Destiny Max in Japan, Italy and Ireland. The high throughput hemostasis analyzer has CE Mark approval in Europe. Trinity Biotech plc (NASDAQ:TRIB), Dublin, Ireland   Business: Diagnostic  ...
Items per page:
1 - 2 of 2